NP
PTPI

NorthRock Partners’s Petros Pharmaceuticals PTPI Stock Holding History

NorthRock Partners’s Portfolio PTPI Stock Details PTPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-461
Closed -$431K – 354
2021
Q3 		$431K Sell
461
-416
-47% -$270K 0.04% 175
2021
Q2 		$686K Sell
877
-473
-35% -$378K 0.06% 113
2021
Q1 		$1.26M Sell
1,350
-190
-12% -$179K 0.11% 72
2020
Q4 		$1.69M Buy
+1,540
New +$1.45M 0.17% 54

Other funds holding PTPI

SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

NorthRock Partners's PTPI Position: Q4 2021 in Review

NorthRock Partners sold out of Petros Pharmaceuticals (PTPI) in Q4 2021, closing a stake of 461 shares — an estimated $431K sold.

NorthRock Partners first reported a position in PTPI in Q4 2020 and held it in 4 quarters. The position peaked at $1.69M in Q4 2020. 18 funds tracked by Wall St. Rank hold PTPI as of Q4 2021.

  • NorthRock Partners reported no remaining Petros Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • NorthRock Partners sold 461 Petros Pharmaceuticals shares in Q4 2021, an estimated $431K.
  • NorthRock Partners first reported a position in Petros Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • NorthRock Partners's Petros Pharmaceuticals position peaked at $1.69M in Q4 2020.
  • 18 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q4 2021.

Based on NorthRock Partners's 13F filing for Q4 2021, filed 7 Feb 2022.